Core Viewpoint - Medline Inc. successfully completed a $6.26 billion IPO, marking the largest IPO globally in 2025 and receiving strong investor interest on its first trading day [1][3][6]. Group 1: IPO Details - Medline debuted on NASDAQ under the ticker MDLN, opening at $35, a nearly 21% increase from the $29 issue price, and closing at $41, a 41.4% rise [3][6]. - The company sold 216 million shares, with the final pricing near the upper end of the guidance range, resulting in a post-IPO valuation exceeding $66 billion [6][7]. - Medline's IPO surpassed the previous record held by CATL's $5.26 billion listing, making it the largest IPO since Rivian's $13.7 billion in 2021 and the fifth largest in the past decade in the U.S. [6][12]. Group 2: Investor Interest and Backing - The IPO was over 10 times oversubscribed, leading to an increase in the number of shares offered from an initial plan of 179 million [7]. - Medline secured $2.35 billion in commitments from cornerstone investors, including Baillie Gifford and Morgan Stanley's Counterpoint Global [7][8]. - The company allocated over 3.7 million shares from the IPO proceeds to repurchase stock from pre-IPO shareholders, allowing private equity firms to realize returns without directly selling shares [7][8]. Group 3: Company Background and Performance - Founded in 1966, Medline manufactures and distributes medical supplies, serving hospitals and clinics with a product range of approximately 335,000 items [8][9]. - The company reported a net income of $977 million and revenue of $20.6 billion for the nine months ending September 27, with a projected annual revenue of $25.5 billion for 2024 [9][11]. - Medline aims to position itself as the "Costco of healthcare," focusing on a strong supply chain and proprietary products [9]. Group 4: Challenges and Strategic Moves - Medline faced challenges in its IPO journey due to uncertainties from tariff policies and government shutdowns, which delayed its initial plans [10][12]. - The company anticipates a pre-tax income loss of $150 million to $200 million due to tariffs in fiscal year 2026 [11]. - Strategic investments have been made under new leadership, including a $905 million acquisition of Ecolab's surgical solutions business and $1.6 billion in capital expenditures over the past five years [11]. Group 5: Market Outlook - Medline's successful IPO has positively influenced market sentiment for future IPOs in 2026, with expectations for significant listings such as SpaceX [6][12]. - The overall IPO market in the U.S. for 2025 exceeded $46 billion, despite challenges faced earlier in the year [12][13].

数据显示，过去十年仅有五家在美国上市的公司IPO募资超过50亿美元，Medline(MDLN.US)以62.6亿美 元位列其中，其余四家为优步(UBER.US)、Lineage(LINE.US)、Rivian Automotive(RIVN.US)和Arm Holdings(ARM.US)。 智通财经APP获悉，周三，美国医疗巨头Medline(MDLN.US)登陆美股市场，开盘报35美元，涨幅超过 20%，IPO价格为29美元。截至发稿，该股涨幅扩大至超25%，报36.62美元。Medline此次IPO募资规模 超过了今年全球最大新股宁德时代(03750)，也高于1月在美国融资17.5亿美元的Venture Global(VG.US)。 ...

周三，美国医疗巨头Medline(MDLN.US)登陆美股市场，开盘报35美元，涨幅超过20%，IPO价格为29美 元。截至发稿，该股涨幅扩大至超25%，报36.62美元。Medline此次IPO募资规模超过了今年全球最大 新股宁德时代（300750）(03750)，也高于1月在美国融资17.5亿美元的Venture Global(VG.US)。 数据显示，过去十年仅有五家在美国上市的公司IPO募资超过50亿美元，Medline(MDLN.US)以62.6亿美 元位列其中，其余四家为优步(UBER.US)、Lineage(LINE.US)、Rivian Automotive(RIVN.US)和Arm Holdings(ARM.US)。 ...

Medline's stock soared more than 40% above its IPO price on Wednesday, its first day of trading. ...

Medline (MDLN) stock rose 40% on Wednesday to close at $40.66, as investors warmly greeted the year's biggest IPO on one of the last trading days of the year. The medical supply giant said late Tuesday that it had raised $6.26 billion in its IPO, selling a little over 216 million shares at $29 each, with the stock set to begin trading on Wednesday. Based on a total Class A share count of around 1.3 billion, the company's market cap stood north of $50 billion at the close of trading on Wednesday. Privat ...

A day that featured the biggest initial public offering in four years also saw the Nasdaq Composite close sharply lower.The tech-heavy index slid 1.8%. The S&P 500 dropped 1.1%. The Dow Jones Industrial Average fell 230 points, or 0.5%. The S&P and Dow extended their respective losing streaks to four days.Struggles for the Nasdaq were in stark contrast to Medline, which surged in its debut on the tech-heavy index under the MDLN ticker. It raised $6.26 billion in the initial public offering, which makes it t ...

Core Insights - Medline Inc. completed a $6.26 billion IPO, marking the largest global IPO of 2025 and receiving strong investor interest on its first trading day [1][3] Group 1: IPO Details - Medline's stock debuted on NASDAQ under the ticker MDLN at an opening price of $35, a nearly 21% increase from the $29 issue price, reaching over $38 during trading, with a peak increase of over 30% [3] - The IPO involved the sale of 216 million shares, with the opening valuation of Medline reaching $47 billion, approximately 40% higher than its valuation during a 2021 acquisition by private equity firms [3][6] - This IPO surpassed the previous record held by CATL's $5.26 billion listing, making it the largest IPO of the year and the largest in the U.S. since Rivian's $13.7 billion IPO in 2021 [3][6] Group 2: Market Impact - Medline's successful IPO contributed to a total IPO fundraising exceeding $46 billion for the year, boosting optimism for the 2026 IPO market, potentially setting the stage for significant listings like SpaceX [4][10] - The IPO received over 10 times the subscription demand, leading to an increase in the number of shares issued from an initial plan of 179 million to 216 million [5] Group 3: Company Background - Medline, founded in 1966, specializes in manufacturing and distributing medical supplies, serving hospitals and clinics with a product range of approximately 335,000 items [6] - The company was acquired by private equity firms Blackstone, Carlyle Group, and Hellman & Friedman in 2021 for up to $34 billion, marking one of the largest leveraged buyouts in history [6] - Medline's CEO, Jim Boyle, aims to position the company as the "Costco of healthcare," emphasizing a strong supply chain and a loyal customer base [7] Group 4: Financial Performance - For the nine months ending September 27, Medline reported a net income of $977 million and revenue of $20.6 billion, compared to $911 million and $18.7 billion in the same period the previous year [7] - The company anticipates a total revenue of $25.5 billion for the full year of 2024 [7] Group 5: Challenges and Strategic Moves - Medline faced challenges in its IPO journey due to uncertainties from U.S. tariff policies and a government shutdown, which delayed its initial plans for a mid-2023 listing [8] - The company has made strategic investments, including a $905 million acquisition of Ecolab Inc.'s surgical solutions business and $1.6 billion in capital expenditures over the past five years to enhance its distribution network [9]

Medline shares surged more than 40% in their hotly anticipated New York debut on Wednesday, valuing the medical supply giant at $54 billion in the largest US initial public offering since Rivian’s 2021 listing, capping a strong year for new listings and fueling optimism for 2026.Shares of the company opened at $35, compared with its IPO price of $29 per share. The stock closed at $41.The medical supplies maker and distributor — acquired for $34 billion in 2021 by Blackstone, Carlyle and Hellman & Friedman i ...

The IPO of the year, the biggest one, uh, popping on its open last hours, just a few minutes ago, really after some middling performance in the IPO market generally. Is it a sign of pent-up demand into mega offerings like SpaceX next year. A sigh of relief for the private equity space, too.Leslie Picker has more over at the NASDAQ. Leslie, hey, Kelly, [music] yes. The largest IPO of the year, Medline, opening for trading about 15 minutes ago at $35 per share.That's up more than 20% from its IPO price of $29 ...

Core Insights - Medical supply firm Medline's stock price increased by approximately 29% on its first day of trading on the Nasdaq [1] - The company raised $6.26 billion, marking the largest initial public offering (IPO) of the year [1] Company Overview - Medline's CEO, Jim Boyle, participated in the opening bell ceremony at the Nasdaq [1]